OP0096 Impact of sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody, on multidomain clinical outcomes in active psoriatic arthritis: results from the randomized, double-blind, placebo-controlled Phase 2 ARGO trial

医学 银屑病性关节炎 安慰剂 双盲 内科学 安慰剂对照研究 随机对照试验 关节炎 物理疗法 免疫学 替代医学 病理
作者
I.B. McInnes,L. Eder,Christopher T. Ritchlin,A. Ogdie,Arthur Kavanaugh,Laura C. Coates,Georg Andreas Schett,A. Kivitz,Nuala Brennan,Alex Godwood,M.R. Thomas,E. Cullen,Kristian Reich,J.F. Merola,Philip J. Mease
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:84: 85-86 被引量:3
标识
DOI:10.1016/j.ard.2025.05.118
摘要

Background: Sonelokimab is a novel IL-17A- and IL-17F-inhibiting Nanobody that binds to both IL-17A and IL-17F with similarly high affinity and is designed to target difficult-to-reach sites of inflammation due to its small size and albumin-binding domain. The randomized, placebo-controlled Phase 2 ARGO trial in patients with active psoriatic arthritis (PsA) met its primary endpoint at Week 12 with sonelokimab 60mg and 120mg (with induction dosing) achieving significantly higher rates of ACR50 vs. placebo [1], with response rates further increasing through Week 24 [2]. The involvement of multiple domains, including skin and joints, in the majority of patients with PsA leads to impaired function and drastically impacts patients' quality of life [3]. Multidomain outcomes that capture disease impact across different tissues and assessment types are therefore important to evaluate. Objectives: Describe the multidomain and high-hurdle outcomes with sonelokimab in the Phase 2 ARGO trial of patients with active PsA. Methods: ARGO (NCT05640245) was a global, randomized, prospective, double-blind, placebo-controlled trial, conducted across 42 sites in Europe and the United States. Eligible patients were ≥18 years old with a confirmed diagnosis of active PsA (Swollen Joint Count [SJC] 66 ≥3; Tender Joint Count [TJC] 68 ≥3) and active psoriasis or a dermatologist-confirmed history of psoriasis. Patients were randomized 1:1:1:1:1 to sonelokimab 60mg with no induction (NI), sonelokimab 60mg or sonelokimab 120mg (every 4 weeks from Week 8, with induction doses at Weeks 0, 2, 4, and 6), placebo, or adalimumab 40mg every 2 weeks (reference arm; not powered for statistical comparison). Randomization was stratified by sex (male/female) and prior biologic use (yes/no). Patients receiving placebo switched to sonelokimab 120mg NI at Week 12. Additionally, patients with SJC and TJC improvement <20% were reassigned treatment at Week 12. Multidomain endpoints included minimal disease activity (MDA) rates and concomitant achievement of ACR70 + PASI 100 (PASI assessed in patients with BSA >3%). Missing data were imputed as non-response. Results: Overall, 207 patients were randomized. At Week 24, up to 61% of patients achieved MDA with sonelokimab (Table 1). When considering pooled data across all sonelokimab arms, ≥50% of patients achieved MDA across key subgroups, including female patients (52%) and patients with a weight ≥100kg (53%), hsCRP levels >ULN (56%), or ≥3% BSA involvement at baseline (55%). Notably, 40% of patients across sonelokimab arms who had active moderate-to-severe psoriasis at baseline (PASI ≥10) also achieved MDA at Week 24 (20% in the adalimumab reference arm). The composite outcome of ACR70 + PASI 100 was achieved by up to 48% of patients receiving sonelokimab at Week 24, demonstrating simultaneous achievement of high-hurdle endpoints across disease domains (Table 1). Robust achievement of ACR70 responses at Week 24 was observed across all sonelokimab dose groups (Table 1), with high rates (>37%) also observed across key subgroups of interest for pooled sonelokimab doses (sex [male vs. female], weight [<100kg vs. ≥100kg], concomitant DMARDs, hsCRP levels [>ULN vs. ≤ULN]). ACR70 was also achieved by up to 39% of patients with more severe joint disease at baseline (DAPSA >28; 120mg dose arm). Additionally, up to 63% of patients achieved complete skin clearance (PASI 100; Table 1), with robust responses also reported across subgroups of interest, including patients with moderate-to-severe psoriasis at baseline (45% achievement across pooled sonelokimab doses). Sonelokimab was well tolerated and there were no unexpected safety findings. There were no cases of IBD, MACE, depression, or SIB. Four cases (2%) of mild or moderate oral candidiasis were recorded. Conclusion: Sonelokimab demonstrated strong efficacy on multidomain clinical outcomes, as well as on individual high-hurdle composite joint and skin response outcomes, with consistent and robust benefits seen across key patient subgroups. There were no unexpected safety findings. Phase 3 studies (IZAR-1: NCT06641076 and IZAR-2: NCT06641089) are ongoing to evaluate sonelokimab 60mg and 120mg in active PsA. REFERENCES: [1] McInnes et al . Efficacy and safety of sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody®, in patients with active psoriatic arthritis (PsA): Results from the global, randomized, double-blind, placebo-controlled Phase 2 ARGO trial. EULAR 2024 (Presentation OP0195). [2] McInnes et al . Efficacy and safety of sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody, in patients with active PsA: 24-week results from a global, randomized, double-blind, placebo-controlled Phase 2 trial. ACR 2024 (Presentation 2582). [3] Ogdie et al. Experiences and treatment preferences in patients with psoriatic arthritis: A cross-sectional study in the ArthritisPower registry. Rheumatol Ther. 2022;9:735–751. Table 1Composite and high-hurdle outcomes at Week 24n, (%)SLK60mg NIn=41SLK60mgn=41SLK120mgn=43ADA refn=42MDA19 (46.3)25 (61.0)22 (51.2)19 (45.2)ACR70 + PASI 100*10 (31.3)9 (34.6)13 (48.1)6 (18.8)ACR7016 (39.0)16 (39.0)18 (41.9)15 (35.7)PASI 100*19 (59.4)16 (61.5)17 (63.0)16 (50.0)NRI, except for patients who switched treatment due to lack of joint response or who completed the study at Week 12 where the last observation during Part A was carried forward.*% based on patients with ≥3% BSA at baseline in the ITT population (SLK 60mg NI, n=32; SLK 60mg, n=26; SLK 120mg, n=27; ADA ref, n=32).ACR, American College of Rheumatology; ADA ref, adalimumab reference; BSA, body surface area; ITT, intention-to-treat; MDA, minimal disease activity; NI, no induction; NRI, non-responder imputation; PASI, Psoriasis Area and Severity Index; SLK, sonelokimab. Acknowledgements: NIL . Disclosure of Interests: Iain B. McInnes has been paid as a speaker for AbbVie, Janssen, UCB, and Novartis, has worked as a paid consultant for AbbVie, Lilly, UCB, MoonLake Immunotherapeutics, Dextera, Novartis, Astra Zeneca, BMS, GSK, Montai, Absci, Compugen, and Cabaletta, has received grants/research support from Lilly, UCB, Dextera, Novartis, Astra Zeneca, and GSK, Lihi Eder has been paid as a speaker for AbbVie, Pfizer, Novartis, Fresenius Kabi, UCB, has worked as a paid consultant for Novartis, Eli Lilly, BMS, Johnson & Johnson, AbbVie, has received grants/research support from Novartis, Eli Lilly, BMS, Johnson & Johnson, AbbVie, Fresenius Kabi, UCB, Christopher T. Ritchlin has worked as a paid consultant for AbbVie, UCB, MoonLake Immunotherapeutics, BMS, Novartis, Janssen, Solarea, Lilly, Alexis Ogdie has worked as a paid consultant for AbbVie, Amgen, BMS, Celgene, Corrona, Gilead, GSK, Janssen, Lilly, Novartis, Spyre, Takeda, TREG, Pfizer, UCB, has received grants/research support from AbbVie (to Penn), Amgen (to Forward), BMS (to Forward), Janssen (to Penn), Novartis (to Penn), Pfizer (to Penn), Forward/National Databank for Rheumatic Diseases, NIH/NIAMS, Rheum Research Foundation, Arthur Kavanaugh has worked as a paid consultant for Amgen, BMS, Lilly, Janssen, Pfizer, Novartis, MoonLake Immunotherapeutics, UCB, Laura C. Coates has been paid as a speaker for AbbVie, Amgen, Lilly, Janssen, Novartis, Pfizer and UCB, has worked as a paid consultant for AbbVie, Amgen, BMS, Lilly, Enlivex, Janssen, MoonLake Immunotherapeutics, Novartis, Pfizer, Takeda and UCB, has received grants/research support from AbbVie, Amgen, Janssen and UCB, Georg Schett: None declared, Alan Kivitz has been paid as a speaker for AbbVie, CME speaker for Excel Continuing Education, GSK, Lilly, Pfizer, Sanofi - Regeneron, UCB, has shares/share options in Pfizer, GSK, Gilead, Novartis, Amgen, has worked as a paid consultant for AbbVie, Coval, Ecor1, Fresenius Kabi, Genzyme, Gilead, Grunenthal, GSK, Halia, Horizon, Innovaderm, Janssen, MoonLake Immunotherapeutics, Pacira, Prime (educational), Prometheus, Santa Ana Bio Inc, Synact, Takeda - Nimbus, UCB, VYNE, XBiotech, Xencor, Nuala Brennan is a shareholder in MoonLake Immunotherapeutics, is an employee of MoonLake Immunotherapeutics, Alex Godwood is a shareholder of MoonLake Immunotherapeutics, is an employee of MoonLake Immunotherapeutics, Matthew R. Thomas has stock options in MoonLake Immunotherapeutics, is an employee of MoonLake Immunotherapeutics, Eva Cullen has presented at congresses as part of current employment with MoonLake Immunotherapeutics, is a shareholder of MoonLake Immunotherapeutics, is an employee of MoonLake Immunotherapeutics, Kristian Reich has been paid as a speaker for LEO Pharma, Lilly Pharma, Almirall S.A. AbbVie, and Janssen-Cilag, is a shareholder of MoonLake Immunotherapeutics, is an employee of MoonLake Immunotherapeutics, has worked as a paid consultant for LEO Pharma, Lilly, Almirall S.A., AbbVie, and Janssen-Cilag, has received grants/research support from LEO Pharma, Lilly, Almirall S.A, and AbbVie, Joseph F. Merola has been a consultant and/or investigator for Amgen, Astra-Zeneca, Boehringer Ingelheim, BMS, AbbVie, Dermavant, Lilly, Incyte, MoonLake Immunotherapeutics, Novartis, Janssen, UCB, Sanofi-Regeneron, Sun Pharma, Biogen, Pfizer and Leo Pharma, has been a consultant and/or investigator for Amgen, Astra-Zeneca, Boehringer Ingelheim, BMS, AbbVie, Dermavant, Lilly, Incyte, MoonLake Immunotherapeutics, Novartis, Janssen, UCB, Sanofi-Regeneron, Sun Pharma, Biogen, Pfizer and Leo Pharma, Philip J. Mease has been paid as a speaker for AbbVie, Amgen, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, UCB, has worked as a paid consultant for AbbVie, Acelyrin, Amgen, BMS, Century, Cullinan Biotech, Lilly, Inmagene, Johnson & Johnson, MoonLake Immunotherapeutics, Novartis, Pfizer, Takeda, UCB, and Genascence (Data Safety Board only), has received grants/research support from AbbVie, Acelyrin, Amgen, BMS, Lilly, Johnson & Johnson, Novartis, Pfizer, UCB. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
粒粒发布了新的文献求助10
1秒前
共享精神的应助被yy采纳,获得10
1秒前
传奇3的应助被柴六斤采纳,获得10
3秒前
晚霞跌落星河的应助被MADAO采纳,获得30
3秒前
3秒前
翟思宇发布了新的文献求助10
4秒前
didida发布了新的文献求助10
4秒前
cc完成签到,获得积分10
4秒前
4秒前
Doran_luffy完成签到,获得积分10
5秒前
pkfsp发布了新的文献求助10
5秒前
水煮电吹风的应助被Chenzhs采纳,获得10
5秒前
6秒前
人生海海发布了新的文献求助10
6秒前
7秒前
Zhb完成签到,获得积分10
7秒前
wangjundong完成签到,获得积分20
8秒前
小安的应助被yu采纳,获得10
8秒前
8秒前
9秒前
9秒前
KOKORO完成签到,获得积分10
9秒前
简单老师发布了新的文献求助10
10秒前
Firsterchao发布了新的文献求助30
11秒前
11秒前
11秒前
11秒前
DW的应助被衣锦夜行采纳,获得10
12秒前
慕青的应助被学术智子采纳,获得10
12秒前
13秒前
leekk完成签到,获得积分10
13秒前
a念完成签到,获得积分10
13秒前
酷波er的应助被魏伯安采纳,获得10
13秒前
yy发布了新的文献求助10
14秒前
岁御无相完成签到 ,获得积分10
14秒前
15秒前
lll发布了新的文献求助10
15秒前
15秒前
CipherSage的应助被errui采纳,获得10
16秒前
冷静冷风完成签到 ,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182102
求助须知:如何正确求助?哪些是违规求助? 9571775
关于积分的说明 21819723
捐赠科研通 7778500
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479651